Lipella Pharmaceuticals Inc. Common Stock
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen plan… Read more
Lipella Pharmaceuticals Inc. Common Stock (LIPO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -1.585x
Based on the latest financial reports, Lipella Pharmaceuticals Inc. Common Stock (LIPO) has a cash flow conversion efficiency ratio of -1.585x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.36 Billion) by net assets ($1.49 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Lipella Pharmaceuticals Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Lipella Pharmaceuticals Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Lipella Pharmaceuticals Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lipella Pharmaceuticals Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Goto Ltd
TA:GOTO
|
N/A |
|
Alternus Energy Group Plc
NASDAQ:ALCE
|
-0.100x |
|
Full Metal Minerals Ltd
PINK:FLMTF
|
0.030x |
|
The GNS Group Inc
PINK:NASO
|
0.296x |
|
UNITED CONTL (UAL1.SG)
STU:UAL1
|
0.131x |
|
MERCURY SYSTEM
MU:MCY
|
-0.010x |
|
Nordea Invest Aktier II KL 1
CO:NDIAKTIIKL1
|
N/A |
|
CSG SYSTEMS INTL
MU:CSN
|
0.137x |
Annual Cash Flow Conversion Efficiency for Lipella Pharmaceuticals Inc. Common Stock (2019–2024)
The table below shows the annual cash flow conversion efficiency of Lipella Pharmaceuticals Inc. Common Stock from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.92 Million | $-3.95 Million | -2.058x | -105.45% |
| 2023-12-31 | $3.14 Million | $-3.15 Million | -1.002x | -155.80% |
| 2022-12-31 | $4.68 Million | $-1.83 Million | -0.392x | +43.64% |
| 2021-12-31 | $1.42 Million | $-989.27K | -0.695x | -1026.69% |
| 2020-12-31 | $463.32K | $-28.58K | -0.062x | -118.66% |
| 2019-12-31 | $-118.34K | $-39.12K | 0.331x | -- |